Last reviewed · How we verify
NCT06224790: PenDaNt
Perfenidone in Type 2 Diabetic Patients With Diabetic Neuropathy
Phase 4 trial testing Pirfenidone in Diabetic Nephropathies in 60 participants. Completed in 7 March 2025.
7 March 2025
Quick facts
| Lead sponsor | Sidrah Lodhi |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 60 |
| Start date | 10 March 2024 |
| Primary completion | 7 March 2025 |
| Estimated completion | 7 March 2025 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- Pirfenidone — full drug profile →
- Placebo
Conditions studied
- Diabetic Nephropathies — all drugs for Diabetic Nephropathies →
- Type 2 Diabetes — all drugs for Type 2 Diabetes →
Sponsor
Sidrah Lodhi
Who can join
Adults 30 to 65, any sex, with Diabetic Nephropathies or Type 2 Diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine the effectiveness \& safety of pirfenidone in type 2 diabetic patients with diabetic nephropathy
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Decoding organ fibrosis: mechanistic insights and emerging therapeutic strategies.
Chen X, Zhang J, Guo L, Wu C, et al · · 2026 · cited 2× · PMID 41786685 · DOI 10.1038/s41392-025-02532-0
Verify or expand the search:
- PubMed search for NCT06224790
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Pirfenidone
Trials testing the same drug.
- NCT06241560 — A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in · Phase 2 · recruiting
- NCT07082842 — Confirmatory Clinical Study of HEC585 Tablets in Patients With IPF · Phase 3 · not yet recruiting
- NCT07015398 — A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in · Phase 1 · completed
- NCT06485635 — Real-life-persistence to Antifibrotic Treatments · completed
- NCT06484153 — Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal Carcin · Phase 1, PHASE2 · not yet recruiting
Other recruiting trials for Diabetic Nephropathies
Currently open trials in the same condition.
- NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting
- NCT07187713 — ACE Reno, Pico Cell Matrix and Its Effect on eGFR in Chronic Kidney Diseases · Phase 4 · recruiting
- NCT06778018 — Nutritional Outcomes of Lotus Seed (Nelumbo Nucifera) on Diabetic Sensorimotor Polyneuropathy · NA · recruiting
- NCT06441591 — Clinical Outcome of Vinpocetine in Diabetic Nephropathy · Phase 2, PHASE3 · recruiting
- NCT06431477 — Efficacy and Safety of Telmisartan Compared With Losartan · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06224790 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sidrah Lodhi
- Last refreshed: 11 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06224790.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing